YMRC
ACAD icon

Yorktown Management & Research Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Yorktown Management & Research Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
25,450
+13,400
+111% +$295K 0.39% 86
2026
Q1 		$268K Hold
12,050
– – 0.22% 174
2025
Q4 		$322K Hold
12,050
– – 0.26% 160
2025
Q3 		$257K Hold
12,050
– – 0.21% 185
2025
Q2 		$260K Buy
+12,050
New +$224K 0.25% 186

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Yorktown Management & Research Company's ACAD Position: Q2 2026 in Review

Yorktown Management & Research Company increased its Acadia Pharmaceuticals (ACAD) stake by 111% in Q2 2026, buying an estimated $295K and bringing the position to 25,450 shares worth $644K. The position accounts for 0.39% of the portfolio, ranked #86.

Yorktown Management & Research Company first reported a position in ACAD in Q2 2025 and has held it in 5 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Yorktown Management & Research Company held 25,450 shares of Acadia Pharmaceuticals worth $644K as of Q2 2026.
  • Yorktown Management & Research Company bought 13,400 Acadia Pharmaceuticals shares in Q2 2026, an estimated $295K.
  • Acadia Pharmaceuticals made up 0.39% of Yorktown Management & Research Company's portfolio in Q2 2026, its #86 holding.
  • Yorktown Management & Research Company first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.